CHTR three-lens brief
Evidence-based stock research on CHTR. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Trading at 3% of its 52-week range — deep in the lower band.
- Trading at 3% of its 52-week range — deep in the lower band.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Underperforming SPY by 10.8pp over 30 days.
- P/E of 3.6 — trading at a value multiple.
- Analyst mean target $225.53 — 71% above current (17 analysts).
CHTR closed at $131.82 (-1.88%) as of 2026-07-10. Market cap: $20.65B. P/E (trailing) 3.6. Price is below the 50-day MA and below the 200-day MA. Positives: p/E of 3.6 — trading at a value multiple.; analyst mean target $225.53 — 71% above current (17 analysts).. Concerns: trading at 3% of its 52-week range — deep in the lower band.; 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $13.60B, net income $1.16B, free cash flow $2.40B. Watching for: 2026-07-24 earnings release (13 days out).
Why three lenses on CHTR, not one.
A single reasoning model has blind spots it doesn’t know about. We examine CHTRacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/CHTR" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath CHTR brief"></iframe>